ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2072

Clinical and Laboratory Features Associated with Pulmonary Involvement in Patients with Inflamatory Myopathy

Sonja Praprotnik1, Katja Perdan-Pikmajer2, Katja Lakota3, Ziga Rotar4 and Alojzija Hocevar5, 1University Medical Centre Ljubljana, Ljubljana, Slovenia, 2University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 3UMC Ljubljana, Ljubljana, Slovenia, 4University Clinical Center, Ljubljana, Slovenia, 5University Medical Center Ljubljana, LJUBLJANA, Slovenia

Meeting: ACR Convergence 2024

Keywords: Autoantibody(ies), Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Polymyositis (PM), dermatomyositis (DM), and anti-synthetase syndrome (AS) are conditions included among idiopathic inflammatory myopathies (IMs).. Interstitial lung disease (ILD) is one of the most severe extra-muscular features.

To identify clinical risk factors associated with ILD in a well-defined monocentric cohort of 213 IM patients.

Methods: Data were prospectively collected between January 2005 and June 2023. Patients were regularly followed for a median of 72.6 months. Clinical data were collected in detail, including general data (ie, age, sex, and time since the first symptoms appeared), clinical manifestation. (type of organ involvement), data on histopathological findings (muscle biopsy), functional (electromyography, pulmonary function tests) and imaging (nailfold capillaroscopy-NC, HRCT). Laboratory data were collected at the same time, including a Hep-2 test, a test to detect antibodies against extractable nuclear antigens and a test to detect myositis-specific antibodies (D-Tek: BlueDiver Dot Myosits)

Results: The median patients age was 63 years (interquartile range 35.1-126.9), 69,7% were females. The frequency of IM subtypes in the cohort are presented in Figure 1. ILD was diagnosed in 77 patients. The most common pattern on HRCT was non-specific interstitial pneumonia (46%) followed by organizing pneumonia (20%). In ILD patients, dyspnoea and cough was the first sign of disease in 48.5% of patients, joint problems in 22.8%, muscle pain and weakness in 20.7%, and skin symptoms in 9.1%. ILD was significantly more frequent in AS (48/54; 88.8%) (p < 0.001), less frequently in PM (3/16; 18,7%) and in DM (9/67;13,4%), and none in statin myopathy. 19 patients with AS and ILD had the amyopathic form of IM. The AS subgroup was statistically significantly associated with the combination of anti-Ro 52 and anti-synthetase (most frequently Jo-1) AB (p< 0,01). There have been 12 ILD in 30 overlap syndromes, mostly overlaps with systemic sclerosis and the dominant AB was anti PM-Scl. We did not find a relationship between any antibody in PM, DM and ILD, but microvasculopathy detected by NC (non-specific abnormalities or systemic sclerosis pattern) was associated with DM-ILD and AS-ILD (p< 0,03). It was not related to the presence of the Raynaud‘s phenomenon, which was present only in 50% of patients with pathological NC.

Conclusion: Pulmonary symptoms may be the first sign of IM, therefore IM should be considered in all patients with ILD.

Anti-Ro 52 ABs, alone or in combination with anti-synthetase AB (mostly anti-Jo-1) are strongly suggestive of ILD. We observed an association between the pathological NC pattern and ILD, even in the absence of Raynaud‘s  phenomenon.

Supporting image 1


Disclosures: S. Praprotnik: None; K. Perdan-Pikmajer: None; K. Lakota: None; Z. Rotar: None; A. Hocevar: None.

To cite this abstract in AMA style:

Praprotnik S, Perdan-Pikmajer K, Lakota K, Rotar Z, Hocevar A. Clinical and Laboratory Features Associated with Pulmonary Involvement in Patients with Inflamatory Myopathy [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/clinical-and-laboratory-features-associated-with-pulmonary-involvement-in-patients-with-inflamatory-myopathy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-laboratory-features-associated-with-pulmonary-involvement-in-patients-with-inflamatory-myopathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology